High Satisfaction with Cladribine Tablets in Gulf RMS Patients
نُشرت في السبت، 12 أغسطس 2023

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
A multicentre observational study in the Arabian Gulf evaluated treatment satisfaction with cladribine tablets (CladT) in 58 relapsing multiple sclerosis (RMS) patients. Results showed high scores for overall satisfaction (77.8%), ease of use (87.4%), tolerability (94.2%), and perceived effectiveness (76.2%). Scores were consistent across demographics and disease characteristics. No relapses or serious adverse events occurred, with lymphopenia reported in 16% of patients. The study underscores CladT’s convenience and effectiveness as a patient-preferred therapy for RMS in the region.